The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GSK’227, now known as risvutatug rezetecan ...

Jace Yawnick, now in remission from non-Hodgkin lymphoma, is navigating the world of mental health one day at a time. Jace Yawnick, now 27-years-old and in remission from non-Hodgkin lymphoma, is ...

At the 2025 ASH Annual Meeting and Exposition, researchers presented new findings that may meaningfully affect how patients ...

Gastric cancer treatment can be especially challenging because patients often struggle with eating, maintaining weight, and ...

Living with chronic cancer involves balancing health precautions with the desire to enjoy life, especially during the ...

The SHARON trial is a phase 1 study testing a new treatment called GO-4 for patients with advanced pancreatic cancer who have ...

Shortly after beginning treatment for stage 3 inflammatory breast cancer, Lindsey Gunter started experiencing rare ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to muzastotug when used in combination with Keytruda (pembrolizumab) to treat adult patients with microsatellite stable ...

Treatment with bleximenib and Venclexta (venetoclax) showed a tolerable safety profile in a phase 1b trial for patients with ...

The U.S. Food and Drug Administration (FDA) has approved Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

The FDA has granted breakthrough therapy designation to INCA033989 for some patients with essential thrombocythemia.